. Gastroesophageal can cers are aggressive and often spread to distant organs early in the disease trajectory. 4 In general, around 16-37% of cancers that reach the submucosal layer (T1b category) have already spread to locoregional lymph nodes 5, 6 . In the Western hemisphere, most patients present with locally advanced or metastatic disease, which mandates the use of systemic chemotherapy, either perioperatively or in the palliative setting.
For patients with gastroesophageal cancer that is not amenable to complete resection owing to metastatic disease, palliative chemotherapy can prolong survival, and improve symptoms and quality of life compared with bestsupportive care (BSC) alone 6 . Chemotherapy combinations comprising platinum compounds (for example, oxaliplatin, or cisplatin) and fluoropyrimid ines ( 5fluorouracil (5FU), capecitabine, or S1) are more effective than fluoropyrimidine monotherapy in the first line setting 7 . The addition of a third chemotherapy agent -docetaxel or epirubicin -in patients with an excellent functional and nutritional status with uncompromised organ functions can improve disease control and tumour response rate, which translates to a very modest overall survival benefit when compared with doublet therapy 8, 9 . Thus, for most patients, the use of chemotherapy doub lets is preferred, owing to a morefavourable toxicity profile and risk-benefit ratio.
Indeed, treatment consisting of a twodrug chemo therapy backbone is often used in practice because targeted therapies are increasingly implemented in the therapeutic algorithm of gastroesophageal cancer. HER2 and VEGFR2 are clinically validated molecular targets in the treatment of advancedstage gastroesophageal cancer. Trastuzumab (a HER2targeting monoclonal antibody) and ramucirumab (an antiVEGFR2 antibody) are considered the standardofcare treatments for meta static gastroesophageal cancer [10] [11] [12] , but the availability of these drugs differs among countries. A recently pro posed treatment algorithm, based on national and inter national guidelines and on our interpretation of the latest published data, is shown in FIG. 1 (REFS 7, (13) (14) (15) .
Patients require new treatment options, particularly when standard therapies are exhausted. Despite advances in the treatment of gastroesophageal cancer, predicting which tumours will become resistant to therapy remains challenging; however, with a greater understanding of molecular classifications of gastroesophageal cancer sub types, we hope to improve patient selection for biological therapy, which should enhance therapeutic benefit and outcomes. Herein, we provide a synopsis of the current awareness of the unique biology of gastroesophageal cancer and discuss the clinically applicability of these findings.
Biology of gastroesophageal cancer
Historically, classification of gastric adenocarcinoma was performed on the basis of histological and clinical characteristics. The key subtypes included: Lauren's dif fuse type that encompassed the signet ring type gastric cancer 16 , with higher propensity for a intraperitoneal metastasis pattern 17 and silencing of CDH1 (REF. 18 ); dis tal gastric cancerintestinal type, arising from precursor lesions in the setting of atrophic gastritis and chronic inflammation due to Helicobacter pylori [19] [20] [21] ; and gastric cardia and GEJrelated to inflammation resulting from gastric acid reflux and lifestyle factors, such as obesity and smoking 22, 23 . Stage for stage, gastric cardia and GEJ tumours have a worse prognosis compared with non diffuse distal tumours 24 , and have the highest incidence of HER2 (ERBB2) amplification 10, 25, 26 . The incidence of distal gastric cancer is decreasing worldwide, but GEJ tumours are rapidly increasing in incidence in the Western hemisphere 27 -most rapidly in the USA, and particularly in young males aged 25-39 years 21 .
H. pylori is a group 1 carcinogen according to the WHO because infection with this bacteria can lead to gastric cancer 28 ; although billions of people world wide are infected with H. pylori, fortunately <1% will develop gastric cancer 29 . This low penetrance of gas tric cancer in infected individuals is probably the result of the interplay between H. pylori virulence factors (vacAs1, vacAm1, and cagA) and certain genetic poly morphisms (IL1B511*T carriers: IL1B511*T/*T or IL1B511*T/*C) 30 . Furthermore, obesity 31 , smoking and alcohol consumption, a diet high in salt 32 , and low cereal fibre 33 and vege table 34 consumption increases the risk of developing gastroesophageal cancers.
Epstein-Barr virus (EBV) infection should be sus pected in gastric adenocarinomas that have a character istic lymphoid infiltrate. This finding suggests that focal EBV infection can occur before neoplastic transforma tion 35 . These infiltrates occur in ~5% of tumours, pre dominantly in men, and stage for stage, are associated with a morefavourable prognosis, despite the fact that most of these tumours are proximally located, which usually portends a worse prognosis to distally located tumours 36 .
Genomics of gastroesophageal cancer
Multiple groups have used genomic analysis technologies, such as largescale genome sequencing, to accelerate our understanding of the molecular basis of gastroesophageal cancer. The Cancer Genome Atlas (TCGA) published a comprehensive molecular charac terization of gastric cancer 37 , in which they evaluated mutations, gene copy number changes, gene expression, and DNA methyla tion across 295 patients with gastric cancer. Historically, this disease has been viewed as a single entity, but data from the TCGA unbiased informatics approach that integrated somatic genomic alterations, methylation status and geneexpression analysis has redefined the disease into four distinct subclasses. First, tumours with EBV infection showed profound hypermethylation, and 80% of these tumours harboured a PIK3CA mutation. Second, tumours with microsatellite instability (MSI) had DNA hypermethylation (with patterns distinct from that observed of EBVpositive tumours) and had elevated somatic mutation rates, with highly recurrent mutations of PIK3CA (42%) and ERBB3 (26%) -with 12% of tumours having alterations of both genes. Third, tumours with chromosomal instability (CIN) showed marked aneuploidy, and although they lacked common mutations in PIK3CA and/or ERBB3, recurrent ampli fications of receptor tyrosine kinase (RTK) genes were observed, most notably HER2 (24%). Finally, tumours lacking aneuploidy and elevated rates of mutation or hypermethylation were termed genomically stable (GS), and were mainly represented in the diffuse histological subtype. The TCGA identified that 30% of these GS tumours harboured novel alterations in components of the Rho signalling pathway, particularly somatic muta tions of RHOA or fusion genes involving RhoGTPase activating proteins (FIG. 2) .
Comprehensive molecular profiling is feasible in routine clinical practice using metastatic tumour speci mens. At the Memorial Sloan Kettering Cancer Center (MSKCC) nextgeneration sequencing and genecopy number analysis is routinely performed on all advanced stage gastric tumours, in line with the institutional
Key points
• Oesophageal and gastric cancers are aggressive tumours that result in more than 1 million deaths annually worldwide • Oesophageal and gastric cancers harbour a high number of genetic and molecular alterations, some of which contribute to an aggressiveness phenotype resulting in early development of drug resistance • A new molecular classification of gastric cancer into four subtypes on the basis of genotypic, epigenetic and proteomic characteristics has been developed • HER2-targeting with trastuzumab remains an important strategy in patients with HER2-positive, advanced-stage gastric cancer; however, novel anti-HER2 targeted drugs are being explored in the advanced-stage and perioperative treatment settings • Antiangiogenic treatment with ramucirumab has proved effective in a biologically unselected patient population with disease progression after first-line therapy • Treatments that target cancer stemness and immune-based therapies are two evolving concepts in the management of advanced-stage gastroesophageal cancer 41 . The Asian Cancer Research Group (ACRG) analysed 300 primary gastric tumours using targeted sequencing, genomewide copynumber data and geneexpression data, and described four molecular subtypes linked to distinct clinical outcomes and prognosis 42 . Their mesenchymallike type tumours (microsatellite stable (MSS/epithelialtomesenchymal transition (EMT) pheno type) includes diffusesubtype tumours with the worst prognosis, which have a tendency to occur at an earlier age, and have the highest frequency of recurrence (63%) of the four subtypes 42 . The ACRG MSI subtype comprises hypermutated intestinalsubtype tumours with the best overall prognosis and the lowest frequency of recurrence (22%) of the four subtypes 42 . Finally, both the p53 (TP53)active (MSS/TP53+) and TP53inactive (MSS/TP53−) subtypes include patients with intermedi ate prognosis and recurrence rates (with respect to the other two subtypes), with the TP53active group show ing a better prognosis than the TP53inactive group 42 . The comparison of the ACRG subtypes with the TCGA genomic subtypes revealed similarities, such as a subset of tumours with MSI, and demonstrated that TCGA GS, EBVpositive, and CIN subtypes were enriched in ACRG MSS/EMT, MSS/TP53+ and MSS/TP53− sub types, respectively 42 ; however, the investigators observed several differences in terms patient demographics of the cohorts, molecular mechanism, driver gene, and progno sis associations 42 . An important difference was that the tumours classified as the CIN subtype by TCGA were present across all ACRG subtypes in the TCGA data set 42 . Also, tumours classified as the GS subtype in the TCGA set were present across all ACRG subtypes 42 . The ACRG describe a substantially lower percentage of Lauren's dif fusesubtype cases in the TCGA cohort (24% in TCGA versus 45% in ACRG), with the majority (57%) of Lauren's diffusesubtype cases classified in the TCGA GS subgroup, compared with only 27% of cases in the similar ACRG MSS/EMT subtype 42 . This finding indicates more heterogeneity in the diffuse subtype tumours included in the ACRG cohort. Other significant differences were seen with regard to the prevalence and distribution of CDH1 and RHOA mutations among the different subtypes. The observed differences in prognosis of the ACRG subtypes seem to be unique to this classification system; when the investigators classified ACRG tumours using the TCGA genomic scheme they demonstrated a much weaker association with the prognosis trend 42 . In summary, the ACRG subtype classification complements the TCGA stratification approach, and supplements it by incorpo rating two key molecular mechanisms related to TP53 activity and EMT, in order to further stratify patients with gastric cancer.
Collectively, these efforts to further characterize gas tric tumours have created a roadmap for patient strati fication and genomeguided trial development. These classifications create a foundation to develop rational therapeutics for distinct groups of patients. One remain ing limitation of all approaches could be the inherent heterogeneity of gastric tumours. One of the foresee able hurdles for the use of molecular signatures in the clinic might also relate to healthcare costs. Multiplexed assays could be developed and applied in gastric can cer, although immunohistochemistry and RNA in situ hybridization techniques could be used. Importantly, the signatures need to be validated in future prospective clinical studies and their clinical relevance needs to be confirmed in trials assessing biologically targeted drugs.
Gastroesophageal PDX programme
Most preclinical studies of gastric cancer have relied on cell lines. TCGA data for gastric cancer 37 reveal that the widely available cell lines have several intrinsic limita tions, including loss of the characteristics of the parental Once PDXs are established, patient DNA samples from normal and tumour tissue, and PDX tumour DNA are analysed with a nextgeneration sequencing to iden tify mutations, small insertion and/or deletions, and structural copynumber aberrations. Primary and PDX tumours exhibit similar histology, mutational profile, and copynumber profiles, suggesting that PDXs rep resent the tumours from which they were derived 43 . In contrast with traditional cell lines, new PDX models that have never been in cell culture and passaged a few times, can be readily annotated for various clinical features, and seem to cluster with the TCGA cancer subtypes 43 .
Hereditary predisposition
Approximately 3% of gastric cancer cases arise in the setting of hereditary diffuse gastric cancer (HDGC) 44 . A substantial portion of families with HDGC have germline inactivating mutations in CDH1, encoding Ecadherin, with 80% penetrance and a very high risk of developing diffuse gastric cancer 45, 46 . In addition, women with a CDH1 mutation have approximately a 40% risk of developing lobular breast carcinoma 44, 47, 48 . Familial gastric cancer is now classified into 'CDH1positive' and 'CDH1negative' tumours 49 . [51] [52] [53] [54] . In 2012, gastric adenocarcinoma and proximal polypo sis of the stomach (GAPPS), a new autosomal dominant syndrome, was described 55 . GAPPS is a unique gastric polyposis syndrome associated with a considerable risk of gastric adenocarcinoma. This syndrome is charac terized by the autosomal dominant transmission of fundic gland polyposis, including areas of dysplasia or intestinaltype gastric adenocarcinoma, restricted to the proximal stomach, and with no evidence of colorectal or duodenal polyposis or other heritable gastrointestinal cancer syndromes 55 . Important summaries of the current knowledge about familial gastric cancer syndromes were published elsewhere in 2015 (REFS 56, 57) .
The vast majority of gastric cancers occur sporadi cally and an association exists between increased gastric cancer risk and blood group -those with blood group A have a ~20% higher risk of gastric cancer than those with groups O, B or AB 58, 59 , indicating increased vulnerability to environmental stressors or an associ ation with genes linked with the bloodgroup antigens. Furthermore, clus tering of H. pylori infection 59 might explain the increased rate of gastric cancer in some families.
HER2-positive disease Prevalence and prognosis
In clinical practice, the HER2 was the first, and only, membranebound RTK to be successfully targeted for the treatment of patients with gastric cancer 60 . In a cohort of 3,665 patient samples, the Trastuzumab for Gastric Cancer study (ToGA) revealed that 810 (22%) were HER2positive according to predefined immunohisto chemistry (IHC) and fluorescence in situ hybrid ization (FISH) criteria 10 . Cancers located at the GEJ have a higher rate of HER2 positivity than distal gastric cancers 10 ; intes tinal cancers, according to Lauren's classification, display a much higher expression level of HER2 compared with diffuse cancer subtypes 10 . In several studies from different regions of the world, the incidence of HER2 positivity in gastric cancer was reported to be lower than in ToGA, ranging from 8-18% 26, [61] [62] [63] [64] [65] . Although HER2 amplification seemed to be associated with a worse prognosis in one study 66 , larger investigations could not confirm HER2 protein expression or gene amplification as an independent prognostic factor [67] [68] [69] . In addition, HER2 status in pre treatment biopsies did not predict enhanced benefit from epirubicinplatinumfluoropyrimidine chemotherapy 70 .
Testing for HER2
Accurate testing for HER2positive status is now man datory to identify patients with gastric cancer who will respond to trastuzumab treatment. Nevertheless, the diagnostic applicability of HER2positivity remains challen ging in gastric cancer, owing to considerable intratumoural heterogeneity (FIG. 3) . This intratumoural HER2; diffuse 1+ Nature Reviews | Clinical Oncology heterogeneity can lead to sampling errors 26, 63 . Matched biopsy and resection specimens of gastric and gastro esophageal adenocarcinoma, nevertheless, show high concordance with regard to HER2 status 71 ; however, a minimum of five biopsies is recommended for reliable HER2 assessment. This relatively high number of biop sies is needed to avoid the sampling errors related to the intratumoural heterogeneity of this biomarker 63 : increas ing the number of biopsies results in a decreased chance of a false negative result. Endoscopists should be aware that smaller sample sizes might decrease the accuracy in selecting patients eligible for antiHER2 therapy [72] [73] [74] [75] . Besides these sampling issues, educational programmes have helped to reduce inter observer differences between pathologists and provide better information regarding patient selection for treatment 76 .
Trastuzumab in stage IV gastric cancer
ToGA showed a significant overall survival benefit for patients with HER2positive advancedstage gastric can cer who were treated with trastuzumab and cisplatinfluoropyrimidine (5FU) chemotherapy. Median overall survival was 13.8 months (95% confidence interval (CI) 12-16 months) in those assigned to trastuzumab plus chemotherapy compared with 11.1 months (10-13 months) in those assigned to chemotherapy alone (hazard ratio 0.74; 95% CI 0.60-0.91; P = 0.0046) 10 . In many countries, trastuzumab in combination with cisplatin and 5FU or capecitabine is now a preferred treatment option for patients with HER2positive gas tric cancers on the basis of data published in the ToGA study (FIG. 1) .
ToGA showed a clear association of the HER2 pro tein immunoreactivity score and the benefit from treat ment with trastuzumab, whereas the role of FISH in detecting any form of HER2 amplification (defined as a HER2:CEP17 ratio ≥2) seemed less important in relation to outcome 10 . By contrast, Spanish investigators found the level of HER2 amplification in a cohort of 90 patients with advancedstage gastric cancer to be significantly predictive of sensitivity to trastuzumabbased chemo therapy and overall survival. A mean HER2/CEP17 ratio of 4.7 was identified as the optimal cutoff value dis criminating sensitive and refractory patients (P = 0.005). Similarly, the optimal cutoff for predicting survival longer than 12 months was 4.45 (P = 0.005), and for sur vival longer than 16 months was 5.15 (P = 0.004) 77 . Of note, identification of patients eligible for trastuzumab treatment is a demanding task. HER2 testing in gastric cancer differs from testing in breast cancer because of inherent differences in tumour biology; gastric cancer more frequently shows heterogeneity and focal staining of HER2 and incomplete membrane staining (FIG. 3) 
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HER2-directed treatments in different settings
Despite a solid preclinical rationale 79 , the RTK inhibitor lapatinib did not show significant antitumoural efficacy in HER2positive advancedstage gastric cancers in two clinical phase III studies 80, 81 . The primary end point was not met in either study; however, subgroup analysis pro vided proofofconcept for some activity of lapatinib in patients with HER2amplified cancers. The problem of postprogression treatment of HER2positive advanced stage gastric cancers is currently unresolved; a phase III study in Asian patients and a randomized phase II study in European patients did not demonstrate that lapatinib is an effective treatment in advancedstage gastric cancer in patients with disease progression following treatment with trastuzumab 80, 82 . In view of the fact that lapatinib monotherapy was ineffective as a salvage treatment in trastuzumab pretreated patients with HER2positive advancedstage breast cancer 83 , the European gastric cancer study tested both lapatinib monotherapy and lap atinib in combination with chemotherapy (capecita bine); nonetheless, in both arms response rates were below the predefined threshold of clinical activity 82 . Pertuzumab is an antibody that binds to HER2 and inhibits its dimerization with other HER recep tors, which is hypothesized to result in slowed tumour growth. When combined with trastuzumab, pertuzumab substantially enhanced the antitumour activity of treat ment in HER2positive human gastric cancer xenograft models 84, 85 . On the basis of pharmacokinetic and safety data, a 840 mg pertuzumab dose given every 3 weeks has been selected for investigation in a phase III study of per tuzumab, trastuzumab and chemotherapy in the firstline setting of patients with HER2positive advancedstage gastric cancer 85, 86 . Trastuzumab emtansine (TDM1; also known in the USA as adotrastuzumab emtansine) is an antibodydrug conjugate consisting of the monoclonal antibody trastuzumab linked to the cytotoxic agent DM1; this agent is currently being investigated in the secondline treatment of advancedstage gastric cancer 87 . However, TDM1 failed to prolong survival compared with taxane treatment in this study, according to data presented early in 2016 (REF. 87 ). Of note, the value of targeting HER2 is almost undetermined in the perioperative setting. Two phase II studies, one from Spain 88 and one from Germany 89 , reported the feasibility of neoadjuvant platinum− 5FUbased chemotherapy with trastuzumab, and reported interesting response rates: 36 patients were included in the Spanish study, and showed preoperative capecitabine/oxaliplatintrastuzumab was feasible. An R0 resection was achieved in 28 patients (78%) and a histopathological complete response was observed in three patients (8.3%). 88 The German study 89 reported histopathological complete responses in 10 out of 45 patients (22.2%) with HER2positive locally advanced gastric cancer who received the combination of trastu zumab and standard chemotherapy. This finding raises hope that high response rates can be achieved with trastuzumab plus chemotherapy combinations in the neoadjuvant setting and might translate into improved survival rates. This hypothesis needs to be confirmed by prospective randomized studies.
Indeed, this research gap will be closed by the ongoing European Organisation for Research and Treatment of Cancer (EORTC) INNOVATION study (NCT02205047) 90 , in which investigators are randomly allocating patients with stages Ib-III gastric and GEJ cancers to receive neoadjuvant chemotherapy alone, chemotherapy plus trastuzumab, or chemotherapy plus trastuzumab and pertuzumab. The Radiation Therapy Oncology Group (RTOG) 1010 study is an ongoing phase III trial (NCT01196390) 91 , in which researchers are evaluating the addition of trastuzumab to trimodality treatment (radiation therapy, paclitaxel, and carboplatin) in patients with HER2positive oesophageal adeno carci noma, including GEJ cancer. In addition, in East Asia, the Japanese Cooperative Oncology Group (JCOG) 1301 ran domized phase II study is underway to assess systemic chemotherapy with and without trastuzumab, followed by surgery in patients with HER2positive advancedstage gastric or GEJ adenocarcinoma with extensive lymphnode metastasis 92 .
Resistance to anti-HER2 treatment
Accumulating evidence supports the benefits of contin uing trastuzumab beyond disease progression in patients with HER2positive breast cancer 93, 94 . The results of these studies suggest that continuing trastuzumab after progressive disease in gastroesophageal cancer is a via ble option; however, large prospective studies in patients with gastroesophageal cancer are needed to confirm this approach. Furthermore, how resistance against HER2directed treatment occurs and how this could be managed are important questions. Some concepts can be gleaned from research in patients with breast cancer, but in patients with gastric cancer, much less is known about potential resistance defining alterations, such as PIK3CA mutations, HER3 dimerization, upregu lation of SRC activity and PTEN loss 95 . Loss of HER2 expres sion occurs in approximately onethird of patients with HER2positive gastric cancer treated with trastuzumab, and presents a possible mechanism for trastu zumab resistance. Upon tumour progression, molecular alterations have been observed in EGFR (13%), TP53 (92%), cellcycle mediators, such as cyclindependent kinases (42%) and in the PI3K/AKT/mTOR axis (21%). 96 These data suggest the need for repeat biopsies to accu rately determine the appropriate use of HER2directed therapy upon tumour progression 96 .
Monitoring of anti-HER2 treatment
The variation in trastuzumab biodistribution owing to tumour burden and individual patient metabolism is well recognized as a reason for incomplete responses in patients with HER2positive breast cancer 97, 98 . Zirconium89 ( 89 Zr)trastuzumab PET enables non invasive simultaneous assessment of HER2 levels in both the primary tumour and all sites of metastases 99, 100 . Thus, 89 Zrtrastuzumab PET might help to elucidate the molecular basis of resistance to trastuzumab in patients with gastroesophageal cancer and facilitate the develop ment of an optimal dose and schedule of HER2targeted agents tailored to the tumour burden in individual patients.
In a preclinical study in xenografted mice 101 , the use of the PET imaging tracer 89 Zrtrastuzumab to specifi cally delineate HER2positive gastric cancer and to monitor the pharmacodynamic effects of the antiHER2 agent afatinib was assessed and proved to be feasible. These findings need to be confirmed in prospective studies in patients treated with antiHER2 therapy for HER2positive gastric cancer.
Targeting other RTK signalling pathways
Targeting other RTKs with monoclonal antibodies or smallmolecule inhibitors has not led to compelling effi cacy thus far in patients with gastric cancer. The reasons for this lack of efficacy are various, ranging from uncer tainty about the relevance of the respective signalling pathways for the progression of advancedstage gastric cancer to appropriate patient selection for specific tar geted treatments. Disappointingly, antiEGFR directed treatment with the monoclonal antibodies cetuximab and panitumumab did not provide survival benefit in two large randomized phase III studies, despite prom ising data from phase II studies [102] [103] [104] [105] . Additionally, erlotinib and gefitinib were found to be ineffective in randomized trials that compared these agents to BSC in patients with oesophageal and GEJ cancers 106, 107 ; however, retrospective biomarker analysis suggests that a subpopulation of patients with tumours harbour ing EGFR amplifications or copynumber gains might bene fit from antiEGFR therapy 102, 103, 108 . Notably, EGFR amplifications seem to be rare in gastroesophageal cancers (occurring in <10% of patients) 102, [108] [109] [110] , and prospective studies with EGFR inhibitors in a patient population enriched for EGFRamplified tumours are currently lacking.
Negative results have also been reported regard ing targeting the HGF/MET axis. Despite promising observations with the antiHGF monoclonal antibody rilotumumab in a randomized phase II study 111, 112 , two phase III studies 113, 114 , one testing rilotumumab, and the other onartuzumab (an antibody that inhibits HGF binding to MET), failed to reach their primary end points and did not lead to an improvement in overall survival. These failures were independent of the inten sity of MET staining in patient samples 113, 114 . Alternative biomarkers to guide patient selection other than MET status by IHC might be required for the promise of anti HGF/MET treatments in gastric cancer to be realized; one such option is MET amplification, which might be a moreappropriate biomarker to select for tumours that will respond to MET inhibitors. Preliminary data showed that some patients with MET amplification (which occurs in <5% of gastric cancers 115 ) can achieve complete responses with MET inhibitors, such as crizotinib or AMG337 (REFS 110, 116) .
To date, FGFR has not been as well explored as a therapeutic target in gastric cancer. Nevertheless, a com prehensive survey of genomic alterations in gastric cancer samples revealed FGFR amplification in a dis tinct and molecularly exclusive subgroup of patients 109 . Importantly, FGFR-amplified gastric cancers had a worse prognosis following curative resection 109 , indicat ing that FGFR amplification may be a genetic 'driver' alteration. The authors, therefore, postulated that FGFR inhibitors might be useful in targeting FGFRamplified tumours 109 . Activation of the FGFR2 pathway was found to be required to drive growth and survival of gastric cancers carrying FGFR2 amplifications, both in vitro and in vivo 117 ; in the TCGA gastriccancer dataset, 9% of CIN tumours and 8% of GS tumours harboured FGFR2 amplification 37 . A randomized phase II study raised doubt about the value of targeting FGFR13, however, at least with the experimental drug AZD4547 (REF. 118 ). AZD4547 binds to and inhibits FGFR, which may result in the inhibition of FGFRrelated signal transduction pathways, and was welltolerated. In the phase II trial of this agent, however, the analysis of progressionfree survival did not reveal any statistically significant dif ference in favour of the AZD4547 arm, compared with the paclitaxel arm, in patients with FGFR2amplified or FGFR2polysomy tumours selected by FISH 118 . Reasons for the lack of efficacy of AZD4547 could be the marked intratumour heterogeneity of FGFR2 ampli fication, and the low concordance with elevated FGFR2 protein expression, as exploratory biomarker analysis revealed 118 . The results of ongoing studies examining other FGFR pathway inhibitors and different biomarker based patient selection strategies, such as FGFR2 copy number in cell free plasma DNA, should be awaited before we abandon these agents 119 . Finally, inhibition of mTOR, a downstream signalling component of these RTK pathways, also failed to pro vide survival benefits in a phase III study 120 . Specifically, second line treatment with everolimus, a small molecule inhibitor of mTOR, did not improve overall survival of patients with advancedstage gastric cancer, compared with placebo 120 . Of note, patients had not been pre selected by any RTK expression analysis or any other biomarker. Treatment with everolimus failed irrespec tive of the type of firstline chemotherapy (fluoro pyrimidines, platinum agents or taxanes), according to preplanned subgroup analyses 120 .
Targeting angiogenesis Altered angiogenesis is a typical feature of neoplasia and hallmark of cancer, and targeting tumour angiogenesis is a wellestablished therapeutic approach 121, 122 . Many key elements of tumour angiogenesis are targets of available drugs and investigational compounds 123 (FIG. 4) .
AntiVEGFR2 therapy is the first biological strategy in an unselected patient population to be associated with a survival benefit in patients with chemotherapy refractory gastroesophageal cancer 11, 12 . Ramucirumab, a fully human monoclonal IgG1 antibody targeting VEGFR2, was investi gated in patients with advanced stage gastric cancer following disease progression dur ing or after firstline chemotherapy. Ramucirumab monotherapy and BSC were more effective than placebo and BSC in this trial 11 , leading to an increase in median survival from 3.8 to 5.2 months (hazard ratio (HR) 0.776, 95% CI 0.603-0.998; P = 0.047). Adverse events reported in the ramucirumab were in the same range in type as well as in frequency as in the BSC arm, except ramucirumab was morefrequently associated with arte rial hyper tension (a class effect of this agent and one that is typical side effect of antiangiogenic drugs), but this effect did not negatively impact quality of life 11 . The efficacy of ramucirumab in treating patients with advancedstage gastric cancer in the secondline setting was in the same range as for singleagent chemotherapy (TABLE 1) ; however studies that compared secondline chemotherapy with BSC or a taxane with irinotecan all showed higher clinically significant adverseevent rates in the chemotherapy treatment arms, and typical irinotecan related or taxanerelated adverse effects [124] [125] [126] [127] . On the basis of these observations, ramucirumab could be a preferred treatment option in patients who have previously received chemotherapy, at least when chemotherapyrelated adverse events, such as alopecia, nausea, diarrhoea, infection or sensory neuropathy, need to be avoided. Of note, the antiVEGFR2 inhib itor apatinib showed similar efficacy to ramucirumab in a randomized phase II study 128 . In the RAINBOW study, ramucirumab was investigated in combination with weekly paclitaxel following a lack of response to firstline platinum and fluoropyrimidine therapy 12 . Overall survival was significantly longer in the ramu cirumab plus paclitaxel group than in the placebo plus paclitaxel group (median 9.6 months versus 7.4 months; HR 0.807 (95% CI 0.678-0.962), P = 0.017) 12 . The com bination of ramucirumab and paclitaxel seems to be the mosteffective current treatment regimen for patients with advancedstage gastric cancer in whom disease progresses following firstline therapy. On the basis of these findings, a new treatment algorithm for sec ondline advancedstage gastric cancer has recently been proposed 13 (FIG. 1) .
Sorafenib, a smallmolecule inhibitor that targets VEGFR2, PDGFR, RET, FLT3 and RAF1 129, 130 , has been demonstrated to result in disease stabilization and encouraging progressionfree survival outcomes in patients with chemotherapyrefractory oesopha geal and GEJ cancer 131 . Regorafenib, which targets several receptors, including VEGFR2, also showed enhanced antitumour activity compared with pla cebo in a randomized phase II study in patients with gastroesophageal cancer after failure of firstline or secondline chemotherapy 132 . These data suggest an important role of angio genesis in the progression of gastroesophageal cancer, although, in the firstline setting, three trials explor ing chemotherapy in combination with either beva cizumab 133, 134 or ramucirumab 135 failed to meet their primary end points. These negative results indicate that, at least in a firstline setting, inhibiting VEGF alone might not be sufficient, and inhibition of multiple compensa tory pathways, such as PDGF and FGFR signalling, might be important. Indeed, preclinical models suggest that upregulation of the PDGF and FGFR pathways provide alternate escape mechanisms that drive disease progres sion during VEGF-VEGFR blockade 136, 137 . Despite these findings, a further phase III randomized trial of ramu cirumab or placebo in combination with cisplatin and capecitabine in the firstline setting in HER2negative gastric cancer has been initiated (NCT02314117) 138 .
In a subgroup analysis, high plasma VEGFA levels and low baseline tumour expression of neuropilin1 were suggested to be predictive of sensitivity to bevaci zumab in Western patients 139 . Whether this observation is attributable to other regional treatment patterns, to drug susceptibility issues in different patient popula tions, or to differences in tumour biology remains to be elucidated. Unfortunately, a biomarkerbased selec tion of patients who might benefit from antiangiogenic treatment is not possible at present.
Targeting cancer stemness
Traditionally, cancer cells within a single tumour have been considered as a homogeneous cell population until relatively late in the course of tumour progression, when hyperproliferation and genetic instability lead to distinct molecular subpopulations. In recent years, how ever, evidence indicates the existence of intratumoural heterogeneity and a hithertounappreciated subclass of neoplastic cells within tumours, termed cancer stem cells (CSCs) 122 . The CSC concept emerged in the mid1990s, when stemcell biologists from the University of Toronto reported that they had isolated rare human leukaemic cells that could initiate leukaemia in immunodeficient mice 140, 141 . Other teams subsequently reported finding CSCs in nonhaematological cancers [142] [143] [144] , including gastric cancers 145 . These cancer cell subpopulations were suggested to evade chemotherapy and radiation, partly because most treatments kill rapidly dividing cells, and CSCs proliferate and divide more slowly than other malignant cells. These CSCs could later regenerate the original tumour or metastasize in other organs 146 . Thus, the concept of combining novel CSCdirected therapies with conventional cytoreduction was postulated with the goal to achieve complete tumour eradication.
The JAK/STAT3 signalling pathway is well known for its role in tumour cell proliferation, survival, invasion, and immunosuppression: activation of this pathway promotes cancer through stem cells and inflammation, among other mechanisms 147 . STAT3 regulates mitochon drial functions, as well as gene expression through epi genetic mechanisms 148 . In gastric cancer, especially in the diffuse subtype (according to the Lauren classification), activation of STAT3 is associated with EMT and resist ance to treatment 149 . BBI608, a smallmolecule inhibitor of STAT3 gene transcription, inhibited 'stemness' gene expression and killed highly tumorigenic and metastatic cancer cells isolated from a variety of cancer types 150 . Moreover, cancer relapse and metastasis were effec tively blocked by BBI608 in immunosuppressed mice 150 . A phase III study 151 is now enrolling patients with advancedstage gastroesophageal adenocarcinoma with disease progression on previous chemotherapy. In this trial, patients will be randomly assigned to receive paclitaxel plus BBI608 or placebo, and a prolongation of overall survival is the primary end point 152 .
Immunotherapy
Evading immune destruction is a recognized hallmark of cancer 122 . Targeting of immune checkpoints and agonists of Tcell activation in melanoma and lung cancer have made their way into clinical practice, although data in gastroesophageal cancer remain immature and immuno therapy should only be used in the framework of a clini cal trial 152 . Nevertheless, oesophageal and gastric cancers might be excellent candidate diseases for immuno therapy, in view of the abundant somatic mutations found in these tumours, which might make the cancer cells more sus ceptible to recognition by the immune system 152 (FIG. 5) , owing to neoepitope presentation on their surfaces that enhances tumour immunogenicity 153 . Results from two phase II studies with data pre sented in 2015 raised hope that a subgroup of patients with advancedstage oesophageal and gastric cancers will bene fit from therapies targeting programmed celldeath protein 1 (PD1) 154, 155 . In one of the two studies 154 , 23 patients with squamouscell carcinoma (SCC) or adenocarcinoma of the oesophagus or GEJ showed promising responses to 10 mg/kg pembroli zumab every 2 weeks. The patients had PD1 ligand 1 (PDL1) expression on ≥1% of cells in tumour nests or PDL1positive stromal bands determined centrally by IHC; they had not responded to standard therapy; had ECOG performance status of 0-1; had no autoimmune disease; and received therapy for up to 2 years or until confirmed progression, unacceptable toxicity, or investi gator decision 155 . Overall response rate (confirmed and unconfirmed) was 23% (n = 5), stable disease as a best response occurred in 18% (n = 4), and progressive dis ease in 59% (n = 13); one patient did not have response assessed at the time of analysis 155 . In the other study 155 , 39 patients with PDL1positive gastric cancers who had received at least one previous line of therapy were treated with pembrolizumab 10 mg/kg every 2 weeks for up to 24 months. In total, 22% achieved an objec tive response confirmed by independent assessment 155 . PDL1 expression level was found to be associated with the overall response rate (1sided P = 0.10). The 6month progressionfree survival rate was 24%, and the 6month overall survival rate was 69% 155 . Preclinical data showed that the dual blockade of PD1 and cytotoxicTlymphocyteassociated anti gen 4 (CTLA4) was associated with increased cytokine release and increased proliferation of CD8+ and CD4+ T cells when compared with blockade of either receptor individually 156 . Furthermore, dual blockade combined with tumour vaccine has been shown to effectively restore the ability of Tcells to eradicate tumours 157 . An ongoing phase Ib/II trial is investigating the activity of nivolumab (another antiPD1 antibody) alone or com bined with ipilimumab (an antiCTLA4 antibody) in patients with advancedstage solid tumours, includ ing some with meta static gastric cancer 158 . Despite the preliminary nature of these data, several multinational phase III studies are assessing the value of PD1 and PDL1 targeting agents in different lines of treatment for patients with advancedstage gastroesophageal cancer. The optimal selection of patients with gastro esophageal cancer for immunotherapy remains to be determined.
Previous studies assessed different cancer vaccines and adoptive immunotherapies for advancedstage gas tric cancers, but none of these approaches reached the level of prospective randomized trials sufficiently pow ered to prove their efficacy. It will be exciting to see if novel technologies based on processing and re infusion of tumourinfiltrating lymphocytes will change the [159] [160] [161] . In 2015, an international consortium published data on gastric cancer immune signatures and their geographical variation 162 . Investigation of >1,600 gastric cancers revealed that tumour immune signatures differ significantly between cancers from Asian and non Asian patients. Gastric cancers from nonAsian patients were associated with enrichment of tumourinfiltrating Tcells as well as Tcell gene expression signatures, including those associated with CTLA4 signalling 162 . Exploratory analysis suggests that these differences in antitumour immunity might contribute to geographi cal differences in clinical outcome. The design of future gastric cancer trials, particularly in immunooncology, should consider differences in antitumour immunity in patients from different geographi cal localities, as these might affect treatment response and clinical outcomes 162 .
Conclusions
Gastroesophageal cancers are a major cause of cancer related morbidity and mortality worldwide. Despite major treatment advances, the prognosis remains poor for both localized and advanced disease stages, owing to the molecular complexity and heterogeneity of gastroesophageal cancer. In recent years, the char acterization of oesophageal and gastric cancer into subtypes based on genotype and histology has evolved, and provides a roadmap for the development of new drugs and combinations, for patient stratification and, therefore, for trials of targeted therapies. Targeting of HER2 is effective in patients with tumour expression of this RTK, in whom trastuzumab prolongs survival in combination with chemotherapy. The novel antiHER2 antibody pertuzumab and the antibody-drugconjugate TDM1 are currently under investigation in this setting. AntiHER2 treatment is now also being studied in the perioperative setting to increase response rates, and ultimately survival, in patients undergoing curative sur gery. Optimal patient selection by testing of HER2 posi tivity remains challenging, however. The roles of EGFR, MET and FGFR as targets for drug therapy remain to be elucidated. To date, randomized studies in poorly selected patient popu lations with respective inhibitors of these RTKs have been unsuccessful in demonstrat ing a clinical benefit. As for antiHER therapy, optimal patient selection remains challenging. Targeting angio genesis is an emerging concept in the management of advancedstage gastroesophageal cancer, and ramu cirumab has been associated with prolonged survival in the secondline, either as a monotherapy or in com bination with paclitaxel. Immunecheckpoint inhibition and inhibition of cancer stemness are other emerging directions for the medical treatment of gastric cancer. Largescale international studies are ongoing and more results will be reported soon. Hopefully, further insights into the molecular characteristics of gastric cancer will stimulate the role of biomarker driven targeted therapy in gastroesophageal cancer, in both the metastatic and perioperative settings. 
